Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Control Bionics Ltd. ( (AU:CBL) ) has issued an announcement.
Control Bionics has signed an agreement with AAC market leader Tobii Dynavox to run a six‑month pilot in five northwestern U.S. states, under which Tobii Dynavox will evaluate offering Control Bionics’ NeuroNode technology alongside its communication aids, replacing a previous U.S. partner. By integrating NeuroNode’s sEMG-based access with Tobii Dynavox’s eye-gaze systems, the collaboration aims to give users an additional, potentially less fatiguing way to control assistive communication technology and, if successful, could pave the way for a broader U.S. rollout and strengthen Control Bionics’ position in the global AAC ecosystem.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
More about Control Bionics Ltd.
Control Bionics Limited is a medical device company specialising in surface electromyography (EMG) technologies that enable people with severe physical and communication impairments to control computers and speech devices through minimal muscle activation. Its core patented NeuroNode wearable and emerging NeuroStrip miniaturised EMG device support augmentative and alternative communication (AAC) and open pathways into broader markets such as health diagnostics, sports performance and rehabilitation, with operations across North America, Australia, Singapore and Japan.
Average Trading Volume: 1,105,065
Technical Sentiment Signal: Buy
Current Market Cap: A$28.43M
Find detailed analytics on CBL stock on TipRanks’ Stock Analysis page.